Anodyne Nanotech Develops Novel Therapy for Sarcopenia with ANN-102 and HeroPatch Microneedle System.

Anodyne Nanotech has announced new preclinical data demonstrating its muscle-preserving therapy, ANN-102, significantly improved muscle strength in aged mice. The treatment targets the APJ receptor, engaging a powerful pathway implicated in several aging-related processes. ANN-102 has shown to stimulate muscle stem cell activity, vascular repair, and improve insulin sensitivity, among other benefits. The data lays the foundation for a novel, non-invasive therapy aimed at addressing sarcopenia, a major health challenge in aging populations.

Anodyne Nanotech, a clinical-stage biotech company, has announced encouraging preclinical data demonstrating the efficacy of its muscle-preserving therapy, ANN-102, in aged mice. The treatment, delivered via the company's proprietary HeroPatch™ microneedle system, significantly improved muscle strength, with efficacy equivalent to daily injections. This breakthrough lays the foundation for a novel, non-invasive therapy aimed at addressing sarcopenia, a major health challenge in aging populations [1].

Sarcopenia, characterized by the progressive loss of muscle mass and strength, is a significant risk factor for chronic diseases, falls, fractures, and loss of independence. It is estimated that by the time individuals reach their 80s or 90s, up to 50% of their muscle mass may be lost, particularly in those who are inactive. The economic burden of sarcopenia-related hospitalizations in adults over 65 is estimated to be $19.1 billion annually in the United States alone [1].

ANN-102 targets the APJ receptor, engaging a powerful pathway implicated in several aging-related processes. Activation of this receptor has been shown to stimulate muscle stem cell activity, vascular repair, improve insulin sensitivity, enhance mitochondrial function, promote fat oxidation, and help regulate appetite. These effects position the APJ pathway as a promising therapeutic target for extending healthspan and addressing the systemic decline associated with aging [1].

In a 20-day study in an aged mouse model, ANN-102 significantly increased grip strength, a common marker of functional muscle performance and a powerful predictor of overall longevity. The treatment was as effective as daily injections with an endogenous APJ RA, demonstrating the potential for a first non-invasive, sustained delivery [1].

Anodyne Nanotech's lead asset is a once-weekly transdermal GLP-1 patch for obesity, entering clinical trials in 2026. Given the company's ability to co-formulate multiple therapeutic agents in a single patch, there is substantial potential to combine GLP-1-based therapies with muscle-preserving agents like an APJ-RA in a single, patient-friendly patch—addressing both obesity and sarcopenia in an integrated approach to healthy aging [1].

Based on these encouraging preclinical results, Anodyne will advance the APJ-RA program toward clinical development. The company is open to strategic partnerships and co-development opportunities to accelerate the path toward delivering this promising muscle-preserving therapy to patients worldwide [1].

References:
[1] https://www.businesswire.com/news/home/20250609538147/en/Anodyne-Nanotech-Drives-Major-Advancement-in-the-Treatment-of-Sarcopenia-with-Novel-Muscle-Preserving-Therapy